Pfizer Takes Step Back With Avelumab, Step Forward On CAR-T
Executive Summary
Major changes to Phase III Lung 100 study of PD-L1 inhibitor avelumab mean a big delay for development in first-line lung cancer, but, separately, Pfizer advances in allogeneic CAR-T therapy with partners Servier and Cellectis.
You may also be interested in...
Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer
The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.
Merck KGaA/Pfizer's Bavencio Set To Enter Europe's Crowded I-O Market
The highly-competitive PD-1 field in Europe is very likely to have a new player as Bavencio gets a CHMP recommendation for Merkel cell carcinoma, but the success of Merck KGaA and Pfizer's checkpoint inhibitor will be gauged on how it competes with the competition already on the market in wider, more valuable indications.
Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"
President-Pfizer Oncology Liz Barrett said the company remains committed to demonstrating the value of Bavencio in first-line lung cancer despite a recent setback that will push data out to 2019.